| scholarly article | Q13442814 |
| P2093 | author name string | Poulam M Patel | |
| Jason Adhikaree | |||
| Aanchal Preet Kaur | |||
| Andrew Mark Jackson | |||
| Julia Moreno-Vicente | |||
| P2860 | cites work | B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion | Q22010866 |
| Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis | Q41283113 | ||
| Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | Q41316099 | ||
| Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone | Q41826343 | ||
| Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy | Q42821853 | ||
| Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck | Q43164702 | ||
| Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases | Q43874383 | ||
| T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. | Q44384732 | ||
| Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection | Q44660955 | ||
| Efficiently stimulated adult microglia cross-prime naive CD8+ T cells injected in the brain. | Q45990565 | ||
| Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations | Q46555595 | ||
| Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143. | Q46675575 | ||
| Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy | Q46934849 | ||
| Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. | Q48325664 | ||
| Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab | Q48376720 | ||
| Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma | Q48584168 | ||
| Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma | Q48616807 | ||
| T Cell Exhaustion Signatures Vary with Tumor Type and are Severe in Glioblastoma | Q50043938 | ||
| High-Dimensional Single-Cell Mapping of Central Nervous System Immune Cells Reveals Distinct Myeloid Subsets in Health, Aging, and Disease | Q50092192 | ||
| Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes | Q50536584 | ||
| Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on α4 integrin | Q50984358 | ||
| Homozygous 10q23/PTEN deletion and its impact on outcome in glioblastoma: a prospective translational study on a uniformly treated cohort of adult patients | Q51825686 | ||
| Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. | Q54597560 | ||
| Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma. | Q55257766 | ||
| Microglial/macrophage expression of interleukin 10 in human glioblastomas. | Q55476902 | ||
| Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. | Q55488698 | ||
| Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers | Q58450835 | ||
| Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system | Q60446155 | ||
| Impaired circulating myeloid CD1c+ dendritic cell function in human glioblastoma is restored by p38 inhibition - implications for the next generation of DC vaccines | Q64268046 | ||
| Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures | Q69005518 | ||
| The glioblastoma-derived T cell suppressor factor/transforming growth factor-beta 2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor | Q69025910 | ||
| Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours | Q72076849 | ||
| Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation | Q73567305 | ||
| Glucocorticoids affect human dendritic cell differentiation and maturation | Q77823491 | ||
| Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study | Q87056653 | ||
| Actively personalized vaccination trial for newly diagnosed glioblastoma | Q90648467 | ||
| Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial | Q90648479 | ||
| Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors | Q90929525 | ||
| Interleukin-10 and the interleukin-10 receptor | Q24290912 | ||
| Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor | Q24561970 | ||
| Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation | Q24675931 | ||
| Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites | Q26798402 | ||
| A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules | Q27308814 | ||
| Structural and functional features of central nervous system lymphatic vessels | Q27316769 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. | Q27853339 | ||
| Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. | Q27853362 | ||
| PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. | Q27853379 | ||
| PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations | Q28075712 | ||
| Astrocyte-endothelial interactions at the blood-brain barrier | Q28131675 | ||
| T cell exclusion, immune privilege, and the tumor microenvironment | Q28259872 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Lymphocyte adhesion and transendothelial migration in the central nervous system: the role of LFA-1, ICAM-1, VLA-4 and VCAM-1. off | Q28581553 | ||
| The chemokine system in diverse forms of macrophage activation and polarization | Q29547719 | ||
| Structure and function of the blood-brain barrier | Q29615699 | ||
| Immunologic correlates of the abscopal effect in a patient with melanoma | Q29620334 | ||
| Nivolumab in previously untreated melanoma without BRAF mutation | Q29620688 | ||
| Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma | Q29620812 | ||
| PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma | Q29620878 | ||
| Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Q30277192 | ||
| Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor | Q30442773 | ||
| Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion | Q30489174 | ||
| Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain | Q31148056 | ||
| Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial | Q33926135 | ||
| Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. | Q33930593 | ||
| Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis | Q33966409 | ||
| Oncology Meets Immunology: The Cancer-Immunity Cycle | Q34037625 | ||
| Corticosteroids in brain cancer patients: benefits and pitfalls | Q34191990 | ||
| Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. | Q34276759 | ||
| Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Review | Q34306352 | ||
| The role of microglia and matrix metalloproteinases involvement in neuroinflammation and gliomas | Q38136195 | ||
| CNS macrophages and peripheral myeloid cells in brain tumours | Q38203815 | ||
| Antiinflammatory effects of glucocorticoids in brain cells, independent of NF-kappa B. | Q38321863 | ||
| Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma | Q38393470 | ||
| Glucocorticoids and Cancer. | Q38555471 | ||
| Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade | Q38727885 | ||
| Coinhibitory Pathways in Immunotherapy for Cancer | Q38755150 | ||
| Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas | Q38760734 | ||
| MYC regulates the antitumor immune response through CD47 and PD-L1 | Q38787131 | ||
| The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition | Q38809779 | ||
| Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. | Q38916367 | ||
| Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer | Q38975751 | ||
| Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors | Q39089944 | ||
| Circulating T regulatory cells migration and phenotype in glioblastoma patients: an in vitro study | Q39100186 | ||
| T cell responses in the central nervous system | Q39110320 | ||
| Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. | Q39118471 | ||
| MYC: Master Regulator of Immune Privilege | Q39149130 | ||
| Clinical significance of FOXP3 expression in human gliomas | Q39167643 | ||
| Corticosteroids compromise survival in glioblastoma | Q39884714 | ||
| Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma | Q40018639 | ||
| Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. | Q40455900 | ||
| RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. | Q40474790 | ||
| Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis | Q40617310 | ||
| High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan | Q40622084 | ||
| Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. | Q40695934 | ||
| Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier | Q40724779 | ||
| Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways | Q41157663 | ||
| Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer | Q34387974 | ||
| Neoantigens in cancer immunotherapy. | Q34470074 | ||
| Combination cancer immunotherapy and new immunomodulatory targets | Q34487698 | ||
| Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy | Q34522172 | ||
| Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity | Q34554995 | ||
| Glioma cancer stem cells induce immunosuppressive macrophages/microglia | Q34992518 | ||
| Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide | Q35167257 | ||
| Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. | Q35168188 | ||
| Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors | Q35570260 | ||
| Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas | Q35796211 | ||
| Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma | Q35815273 | ||
| Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma | Q35863183 | ||
| Molecular mechanisms of brain tumor edema | Q35961516 | ||
| Glucocorticoids in T cell apoptosis and function. | Q36325611 | ||
| IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival | Q36405905 | ||
| Regulatory T cells, tumour immunity and immunotherapy | Q36430144 | ||
| PD-L1 expression and prognostic impact in glioblastoma | Q36493843 | ||
| Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. | Q36553576 | ||
| Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma | Q36730827 | ||
| Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development | Q36874299 | ||
| FcRn: the neonatal Fc receptor comes of age. | Q36912134 | ||
| The role of microglia and macrophages in glioma maintenance and progression | Q36924298 | ||
| The controversial role of microglia in malignant gliomas | Q37091110 | ||
| The role of microglia in central nervous system immunity and glioma immunology | Q37206898 | ||
| Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma | Q37222679 | ||
| MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. | Q37331928 | ||
| Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas | Q37435455 | ||
| The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma | Q37471704 | ||
| Dendritic cell therapy of high-grade gliomas. | Q37594834 | ||
| A systematic review of the literature on the effects of dexamethasone on the brain from in vivo human-based studies: implications for physiological brain imaging of patients with intracranial tumors | Q37812246 | ||
| Microglial cell origin and phenotypes in health and disease | Q37949246 | ||
| The anatomical and cellular basis of immune surveillance in the central nervous system. | Q38035711 | ||
| Capture, crawl, cross: the T cell code to breach the blood–brain barriers | Q38038445 | ||
| Drainage of Cells and Soluble Antigen from the CNS to Regional Lymph Nodes | Q38108499 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P921 | main subject | glioblastoma | Q282142 |
| immunotherapy | Q1427096 | ||
| P577 | publication date | 2020-01-21 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Cells | Q27724621 |
| P1476 | title | Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma | |
| P478 | volume | 9 |
| Q89948335 | Meningeal lymphatics "drain" brain tumors | cites work | P2860 |
Search more.